Trial Profile
A Randomised, Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of Multiple Doses of Orally Administered EDP-938 Against Respiratory Syncytial Virus Infection in the Virus Challenge Model
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Nov 2023
Price :
$35
*
At a glance
- Drugs Zelicapavir (Primary)
- Indications Respiratory syncytial virus infections
- Focus Pharmacokinetics; Proof of concept
- Sponsors Enanta Pharmaceuticals
- 20 Nov 2023 According to an Enanta Pharmaceuticals media release, data from this study has been presented at IDWeek 2023.
- 07 Sep 2023 According to an Enanta Pharmaceuticals media release, data from this study will be presented at IDWeek 2023
- 17 Feb 2022 According to an Enanta Pharmaceuticals media release, data from this trial published in the New England Journal of Medicine (NEJM).